Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

1375P Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan

Autor: T. Kita, Yuka Fujita, Atsuhisa Tamura, Mototsugu Shimokawa, T. Endo, N. Sukoh, R. Saito, Y. Okano, Mitsuhiro Takenoyama, Shinji Atagi, M. Kanazu, M. Motegi, S. Takata, Masahide Mori

Publikováno v: Annals of Oncology. 31:S877

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2122d029f3e56932618697b469a08779
https://doi.org/10.1016/j.annonc.2020.08.1689

Zobrazit plný text záznamu

The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)

Autor: Y. Kinoshita, Y. Taniguchi, T. Hirashima, Satoshi Hara, Junji Uchida, Y. Fukuda, H. Matsumoto, N. Sawa, Toshihide Yokoyama, Akihiro Tamiya, Katsuya Hirano, M. Kanazu, Motohiro Tamiya, D. Fujimoto, Hideyuki Suzuki, K. Hosoya, R. Kominami, Toru Kumagai, M. Morita

Publikováno v: Annals of Oncology. 30:v623-v624

Background Pembrolizumab (Pem) for NSCLC and PD-L1 TPS ≥50% as a first-line therapy showed the longer PFS and OS compared with chemotherapy in some clinical trial. However, only limited patients in good general condition without organ failure can p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9257eacd4fc58cc462cb0ea17857c9d
https://doi.org/10.1093/annonc/mdz260.042

Zobrazit plný text záznamu

Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study

Autor: Madoka Kimura, T. Hirashima, Shoichi Ihara, K. Komuta, Masahide Mori, Takayuki Shiroyama, Fumio Imamura, Izumi Nagatomo, Hideyuki Suzuki, M. Kanazu

Publikováno v: Annals of Oncology. 30:ix169

Background Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the standard therapy for advanced non-small cell lung cancer (NSCLC) with common EGFR mutations. However, the efficacy of EGFR-TKIs in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e440921d766f12cb9a0690c20fe81434
https://doi.org/10.1093/annonc/mdz437.028

Zobrazit plný text záznamu

Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan

Autor: M. Kanazu, Atsuhisa Tamura, T. Kita, Mototsugu Shimokawa, T. Endo, S. Takata, N. Sukoh, Mitsuhiro Takenoyama, Y. Okano, Yuka Fujita, Shinji Atagi, Masahide Mori, M. Motegi, Muneaki Shimada, R. Saito

Publikováno v: Annals of Oncology. 30:ix174

Background Previous studies have developed risk stratiﬁcation schemas to assess chemotherapy toxicity. However, the geriatric assessment variables that should be used to assess the individual risk of severe chemotherapy toxicity and clinical outcom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4bd9b527e50f50ff576d80f9d324243
https://doi.org/10.1093/annonc/mdz437.041

Zobrazit plný text záznamu

Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study

Publikováno v: Annals of Oncology. 30:v621

Background Little is known about the associations between treatment outcome for immune checkpoint inhibitors and metastatic sites in patients with advanced non-small cell lung cancer (NSCLC). Furthermore, these previous studies included patients irre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::284ea554432955f34f27d0e6332fd635
https://doi.org/10.1093/annonc/mdz260.036

Zobrazit plný text záznamu

Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan

Autor: T. Kita, Y. Okano, S. Takata, M. Kanazu, Atsuhisa Tamura, N. Sukoh, R. Saito, Masahide Mori, Mototsugu Shimokawa, T. Endo, M. Motegi, Mitsuhiro Takenoyama, Shinji Atagi, Yuka Fujita

Publikováno v: Annals of Oncology. 30:v647

Background Previous studies have developed risk stratiﬁcation schemas to assess chemotherapy toxicity. However, it is controversial which geriatric assessment variables should be used to assess the individual risk of severe toxicity from chemothera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e694b75428028260f83cf229443c76a9
https://doi.org/10.1093/annonc/mdz260.093

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání